Remdesivir interactions
Full monograph for RemdesivirCheck it against another medicine
Medicines
256 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Chloroquine Phosphate | Major | Antagonism | Coadministration with chloroquine or hydroxychloroquine may reduce the therapeutic effects of remdesivir. Drug-drug interaction studies with remdesivir have… | 2 sources — open the full entry |
| Hydroxychloroquine Sulphate | Major | Antagonism | Coadministration with chloroquine or hydroxychloroquine may reduce the therapeutic effects of remdesivir. Drug-drug interaction studies with remdesivir have… | 2 sources — open the full entry |
| Abemaciclib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Abiraterone Acetate | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Acarbose | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Acitretin | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| AcyclovirInjectionOphthalmicOral | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Adefovir Dipivoxil | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Afatinib Dimaleate | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Alectinib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Ambrisentan | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Amikacin | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Amoxicillin + Clavulanic Acid | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Amphotericin B | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Theoretical concerns exist that coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of… | 5 sources — open the full entry |
| Atomoxetine Hydrochloride | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Axitinib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient…2 documented mechanisms | 5 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Excretion · Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from…2 documented mechanisms | 10 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Bicalutamide | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Bromfenac Sodium | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Bupropion Hydrochloride | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Captopril | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Theoretical concerns exist that coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of… | 5 sources — open the full entry |
| Carboplatin | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Carmustine | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Caspofungin Acetate | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Ceritinib | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Cisplatin | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Clarithromycin | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
| Clindamycin + Tretinoin | Moderate | Synergy | Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from… | 5 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.
What to do: Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.
5 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Gilead Sciences, Inc "About Remdesivir. https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir" (2020):
- European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf" (2020):
- US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) https://www.fda.gov/media/137566/download" (2020):
Conditions
Conditions in which Remdesivir needs care, as documented in this source.
Kidney Diseases
MajorPharmacokinetics of remdesivir have not been evaluated in patients with renal dysfunction. All patients must have estimated glomerular filtration rate (eGFR) determined before starting this drug and during therapy as clinically appropriate. The excipient betadex sulfobutyl ether sodium is renally cleared and accumulates in patients with reduced renal function; administration of drugs formulated with betadex sulfobutyl ether sodium (such as this drug) is not recommended in patients with eGFR less than 30 mL/min.
1 source
- "Product Information. Veklury (remdesivir)." Gilead Sciences (2020):
Liver Diseases
ModeratePharmacokinetics of remdesivir have not been evaluated in patients with liver dysfunction. Hepatic laboratory testing should be performed in all patients before starting this drug and during therapy as clinically appropriate. Caution is recommended.
1 source
- "Product Information. Veklury (remdesivir)." Gilead Sciences (2020):